← Back

Wire · opportunities

Merck and Isomorphic Labs Enter Strategic Research Collaboration

Published

20 November 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at merck.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

Merck and Isomorphic Labs have launched a strategic collaboration to use AI-driven drug design alongside Merck's proprietary data to discover new oncology small molecule candidates. Isomorphic Labs will handle AI-based molecular design while Merck manages development and commercialization.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Founders in AI drug discovery can expect growing collaboration models where AI teams supply molecular designs and pharma companies handle trials and sales. You need to position your tech as a critical innovation layer that pharma cannot easily replicate.

◆ Coverage

1 source · 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechai-drug-designpharma-collaborationoncologydrug-discoverybiotech-ai